Cargando…
Genetic Alterations in Anaplastic Thyroid Carcinoma
INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare but fatal thyroid cancer responsible for majority of thyroid cancer related mortality. ATC may originate de novo or from preexisting differentiated thyroid cancer. Complex interaction between different gene mutation has been suggested to be the m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844173/ https://www.ncbi.nlm.nih.gov/pubmed/31741910 http://dx.doi.org/10.4103/ijem.IJEM_321_19 |
_version_ | 1783468384921321472 |
---|---|
author | Rashid, M. Agarwal, Amit Pradhan, Roma George, Nelson Kumari, Niraj Sabaretnam, M Chand, Gyan Mishra, Anjali Agarwal, Gaurav Mishra, Saroj Kanta |
author_facet | Rashid, M. Agarwal, Amit Pradhan, Roma George, Nelson Kumari, Niraj Sabaretnam, M Chand, Gyan Mishra, Anjali Agarwal, Gaurav Mishra, Saroj Kanta |
author_sort | Rashid, M. |
collection | PubMed |
description | INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare but fatal thyroid cancer responsible for majority of thyroid cancer related mortality. ATC may originate de novo or from preexisting differentiated thyroid cancer. Complex interaction between different gene mutation has been suggested to be the main causative factor for origin of ATC in both pathways. Mostly affected pathways are MAP kinase and PI3CA kinase. Hence, we decided to study the frequent alterations in both the pathways in ATC patients. METHODOLOGY: Clinico-pathological data of 34 ATC patients were collected retrospectively and Formalin Fixed Paraffin Embedded (FFPE) blocks were taken out for genetic analysis. DNA and RANA were isolated from FFPE tissues. BRAF V600E mutations were screened by RFLP PCR method and confirmed by sequencing. RAS, PI3CA and p53 mutations were checked by sequencing. RET/PTC translocations were screened by Real Time PCR. RESULTS: A total of 34 patients were studied: Mean age 58.6+ 11.6 years with F:M- 1.8:1, 60% had history of goiter. Most common presenting symptom was rapidly growing thyroid mass followed by dyspnea, dysphasia and hoarseness of voice. Extent of disease was local, locoregional and metastatic in 32%, 35% and 33% respectively. 57.6% were euthyroid, 20.5 % were hyperthyroid while functional status were not available in 11.7%. FNAC was suggestive of ATC only in 52.9% cases. 15 (44%) were operated. BRAF V600E mutations were observed in 10/34 (29.4%). Interestingly, all three ATC patients with DTC components had previous history of goiter with rapid increase in size and BRAF V600E mutation, while BRAF was positive only in 7/31 (22.5%) of patients with no DTC component. Mean survival of 3.5 months in BRAF positive cases in comparison to 5.5 months in BRAF negative ATC. RAS mutations were found to be positive in 5.8%, and none had RET-PTC/PI3CA mutations. P53 mutation was positive in 7 patients. 3 patients presented with history of rapid increase in size of previous goiter while rest 4 patients presented with rapidly increasing thyroid swelling of 1 to 3 months. At presentation 2 patients has disease localized to thyroid, 4 has loco-regional disease and one patient presented with metastasis. 5 out of these 7 patients were operated (Total thyroidectomy:3, thyroidectomy with neck dissection:2). Mean survival was 4 months (1-6 months). CONCLUSION: BRAF V600E was the commonest mutation followed by p53 of the 5 genes tested and BRAF was more common in patients with previous history of longstanding goiter or differentiated thyroid cancer. This provides an indirect evidence of neoplastic transformation of PTC to ATC. |
format | Online Article Text |
id | pubmed-6844173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-68441732019-11-18 Genetic Alterations in Anaplastic Thyroid Carcinoma Rashid, M. Agarwal, Amit Pradhan, Roma George, Nelson Kumari, Niraj Sabaretnam, M Chand, Gyan Mishra, Anjali Agarwal, Gaurav Mishra, Saroj Kanta Indian J Endocrinol Metab Original Article INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare but fatal thyroid cancer responsible for majority of thyroid cancer related mortality. ATC may originate de novo or from preexisting differentiated thyroid cancer. Complex interaction between different gene mutation has been suggested to be the main causative factor for origin of ATC in both pathways. Mostly affected pathways are MAP kinase and PI3CA kinase. Hence, we decided to study the frequent alterations in both the pathways in ATC patients. METHODOLOGY: Clinico-pathological data of 34 ATC patients were collected retrospectively and Formalin Fixed Paraffin Embedded (FFPE) blocks were taken out for genetic analysis. DNA and RANA were isolated from FFPE tissues. BRAF V600E mutations were screened by RFLP PCR method and confirmed by sequencing. RAS, PI3CA and p53 mutations were checked by sequencing. RET/PTC translocations were screened by Real Time PCR. RESULTS: A total of 34 patients were studied: Mean age 58.6+ 11.6 years with F:M- 1.8:1, 60% had history of goiter. Most common presenting symptom was rapidly growing thyroid mass followed by dyspnea, dysphasia and hoarseness of voice. Extent of disease was local, locoregional and metastatic in 32%, 35% and 33% respectively. 57.6% were euthyroid, 20.5 % were hyperthyroid while functional status were not available in 11.7%. FNAC was suggestive of ATC only in 52.9% cases. 15 (44%) were operated. BRAF V600E mutations were observed in 10/34 (29.4%). Interestingly, all three ATC patients with DTC components had previous history of goiter with rapid increase in size and BRAF V600E mutation, while BRAF was positive only in 7/31 (22.5%) of patients with no DTC component. Mean survival of 3.5 months in BRAF positive cases in comparison to 5.5 months in BRAF negative ATC. RAS mutations were found to be positive in 5.8%, and none had RET-PTC/PI3CA mutations. P53 mutation was positive in 7 patients. 3 patients presented with history of rapid increase in size of previous goiter while rest 4 patients presented with rapidly increasing thyroid swelling of 1 to 3 months. At presentation 2 patients has disease localized to thyroid, 4 has loco-regional disease and one patient presented with metastasis. 5 out of these 7 patients were operated (Total thyroidectomy:3, thyroidectomy with neck dissection:2). Mean survival was 4 months (1-6 months). CONCLUSION: BRAF V600E was the commonest mutation followed by p53 of the 5 genes tested and BRAF was more common in patients with previous history of longstanding goiter or differentiated thyroid cancer. This provides an indirect evidence of neoplastic transformation of PTC to ATC. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6844173/ /pubmed/31741910 http://dx.doi.org/10.4103/ijem.IJEM_321_19 Text en Copyright: © 2019 Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Rashid, M. Agarwal, Amit Pradhan, Roma George, Nelson Kumari, Niraj Sabaretnam, M Chand, Gyan Mishra, Anjali Agarwal, Gaurav Mishra, Saroj Kanta Genetic Alterations in Anaplastic Thyroid Carcinoma |
title | Genetic Alterations in Anaplastic Thyroid Carcinoma |
title_full | Genetic Alterations in Anaplastic Thyroid Carcinoma |
title_fullStr | Genetic Alterations in Anaplastic Thyroid Carcinoma |
title_full_unstemmed | Genetic Alterations in Anaplastic Thyroid Carcinoma |
title_short | Genetic Alterations in Anaplastic Thyroid Carcinoma |
title_sort | genetic alterations in anaplastic thyroid carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844173/ https://www.ncbi.nlm.nih.gov/pubmed/31741910 http://dx.doi.org/10.4103/ijem.IJEM_321_19 |
work_keys_str_mv | AT rashidm geneticalterationsinanaplasticthyroidcarcinoma AT agarwalamit geneticalterationsinanaplasticthyroidcarcinoma AT pradhanroma geneticalterationsinanaplasticthyroidcarcinoma AT georgenelson geneticalterationsinanaplasticthyroidcarcinoma AT kumariniraj geneticalterationsinanaplasticthyroidcarcinoma AT sabaretnamm geneticalterationsinanaplasticthyroidcarcinoma AT chandgyan geneticalterationsinanaplasticthyroidcarcinoma AT mishraanjali geneticalterationsinanaplasticthyroidcarcinoma AT agarwalgaurav geneticalterationsinanaplasticthyroidcarcinoma AT mishrasarojkanta geneticalterationsinanaplasticthyroidcarcinoma |